New drug cocktail shows promise for tough lung cancer

NCT ID NCT05351788

Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of drugs (SKB264 plus KL-A167, with or without chemotherapy) in about 110 adults with advanced or metastatic non-small cell lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow cancer growth. Participants must have a specific type of lung cancer that has not been treated much before.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL-CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, China

Contact